유전체 소변 검사 시장 보고서(2025년)

Genomic urine testing is a non-invasive diagnostic approach that examines genetic material found in urine to identify specific biomarkers associated with various diseases, including cancer, infections, and genetic disorders. This method integrates genomics with advanced molecular techniques to detect mutations, gene expression profiles, or microbial DNA (deoxyribonucleic acid). Its main goal is early disease detection, ongoing monitoring, and the development of personalized treatment strategies for different health conditions.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of genomic urine testing include DNA testing, RNA testing, microbial testing, and epigenetic testing. DNA (deoxyribonucleic acid) testing is a scientific technique used to study an individual's genetic makeup to determine biological relationships, verify identity, or uncover inherited health conditions. These tests are distributed through several channels, such as hospital pharmacies, mail-order pharmacies, and specialty pharmacies. Genomic urine tests are applied in areas such as cancer detection, infectious disease diagnosis, genetic disorder screening, and general health assessment. They cater to a broad spectrum of end users, including hospitals and clinics, diagnostic labs, research and academic institutions, and other healthcare providers.

The genomic urine testing market research report is one of a series of new reports from The Business Research Company that provides genomic urine testing market statistics, including the edge artificial intelligence integrated circuits industry global market size, regional shares, competitors with the genomic urine testing market share, detailed genomic urine testing market segments, market trends, and opportunities, and any further data you may need to thrive in the genomic urine testing industry. This genomic urine testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The genomic urine testing market size has grown rapidly in recent years. It will grow from$0.90 billion in 2024 to $1.01 billion in 2025 at a compound annual growth rate (CAGR) of 12.9%. The growth during the historical period can be credited to the rising occurrence of urologic cancers, heightened demand for early cancer diagnosis, increased awareness of precision medicine, a growing number of genetic disorder cases, and expanding investments in biomarker research.

The genomic urine testing market size is expected to see rapid growth in the next few years. It will grow to$1.62 billion in 2029 at a compound annual growth rate (CAGR) of 12.5%. The anticipated growth in the forecast period can be attributed to the rising adoption of liquid biopsy methods, an increasing emphasis on personalized medicine, a growing prevalence of chronic kidney diseases, heightened focus on at-home diagnostic testing solutions, and the expanding application of multi-omics approaches in urine-based testing. Key trends expected during the forecast period include the development of non-invasive diagnostic methods, advancement of high-sensitivity testing panels, integration of machine learning technologies, innovations in urine exosome isolation, and progress in single-cell urine sequencing.

The growing burden of chronic kidney disease is anticipated to drive the expansion of the genomic urine testing market in the coming years. Chronic kidney disease is a condition where the kidneys are damaged and unable to effectively filter blood, leading to an accumulation of waste and fluids in the body. This burden is increasing largely due to the rising prevalence of diabetes, as high blood sugar levels can damage kidney blood vessels, reducing their filtering capability. Genomic urine testing supports the management of chronic kidney disease by enabling early detection of genetic markers, which allows for timely intervention and personalized treatment plans. This approach improves patient outcomes by facilitating more accurate monitoring and slowing disease progression. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency based in Australia, reported that mortality rates due to chronic kidney disease increased from 4.2% in 2021 to 6.2% in 2022. As a result, the escalating burden of chronic kidney disease is contributing to the growth of the genomic urine testing market.

Leading companies in the genomic urine testing industry are concentrating on innovative advancements, such as next-generation sequencing, to improve the precision, sensitivity, and early detection potential of non-invasive diagnostic tests for various illnesses. Next-generation sequencing is a sophisticated DNA sequencing method that facilitates fast, accurate, and large-scale analysis of genetic material by sequencing millions of DNA fragments simultaneously. For instance, in May 2023, Convergent Genomics Inc., a biotechnology company based in the United States, introduced the genomic urine test UroAmp. This test utilizes next-generation DNA sequencing to detect mutations in 60 genes linked to bladder cancer, allowing for early detection up to 12 years before symptoms appear. It offers comprehensive genetic data to support diagnosis, treatment planning, and recurrence monitoring, delivering greater accuracy than conventional techniques such as cytology and cystoscopy.

In September 2024, A. Menarini Diagnostics, an in-vitro diagnostics company headquartered in Italy, formed a partnership with Nucleix Ltd. The collaboration is focused on the commercialization and distribution of Bladder EpiCheck, a non-invasive genomic urine test designed for the early detection and monitoring of bladder and upper tract urothelial cancers throughout Europe. This initiative enhances the availability of advanced cancer diagnostic tools and aligns with clinical guidelines in Europe. Nucleix Ltd. is an Israel-based molecular diagnostics firm that specializes in epigenetic and genomic testing technologies.

Major players in the genomic urine testing market are Eurofins Scientific SE, Thermo Fisher Scientific, Abbott Laboratories, Laboratory Corporation of America Holdings, Hologic Inc., Illumina Inc., Myriad Genetics Inc., ARUP Laboratories, MedGenome Labs Ltd, GENETWORx LLC, MDxHealth SA, Nucleix Ltd., Pacific Edge Ltd, Convergent Genomics Inc., LynxDx Inc., miR Scientific, RYND Biotech, UGenDx Ltd.

North America was the largest region in the genomic urine testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in genomic urine testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the genomic urine testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The genomic urine testing market includes of revenues earned by entities by providing services such as early disease detection, genetic mutation analysis, cancer screening, infection diagnostics, personalized treatment planning, and monitoring of disease progression through non-invasive urine-based genomic profiling. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Genomic Urine Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on genomic urine testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for genomic urine testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The genomic urine testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Testing Type: Deoxyribonucleic Acid (DNA) Testing; Ribonucleic Acid (RNA) Testing; Microbial Testing; Epigenetic Testing
• 2) By Distribution Channel: Hospital Pharmacies; Mail Order Pharmacies; Speciality Pharmacies
• 3) By Application: Cancer Diagnosis; Infectious Diseases; Genetic Disorder Screening; Health Monitoring
• 4) By End-User: Hospitals And Clinics; Diagnostic Laboratories; Research And Academic Institutions; Other End Users
• Subsegments:
• 1) By Deoxyribonucleic Acid Testing: Germline Mutation Analysis; Somatic Mutation Detection; Copy Number Variation (CNV) Testing; Single Nucleotide Polymorphism Analysis
• 2) By Ribonucleic Acid Testing: Gene Expression Profiling; Messenger Ribonucleic Acid Analysis; Non-coding Ribonucleic Acid Detection; Fusion Transcript Detection
• 3) By Microbial Testing: Urinary Microbiome Profiling; Pathogen Identification; Antimicrobial Resistance Gene Detection; Quantitative Microbial Load Analysis
• 4) By Epigenetic Testing: Deoxyribonucleic Acid Methylation Analysis; Histone Modification Profiling; Chromatin Accessibility Testing
• Companies Mentioned: Eurofins Scientific SE; Thermo Fisher Scientific; Abbott Laboratories; Laboratory Corporation of America Holdings; Hologic Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Genomic Urine Testing Market Characteristics

3. Genomic Urine Testing Market Trends And Strategies

4. Genomic Urine Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Genomic Urine Testing Growth Analysis And Strategic Analysis Framework

• 5.1. Global Genomic Urine Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Genomic Urine Testing Market Growth Rate Analysis
• 5.4. Global Genomic Urine Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Genomic Urine Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Genomic Urine Testing Total Addressable Market (TAM)

6. Genomic Urine Testing Market Segmentation

• 6.1. Global Genomic Urine Testing Market, Segmentation By Testing Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Deoxyribonucleic Acid (DNA) Testing
• Ribonucleic Acid (RNA) Testing
• Microbial Testing
• Epigenetic Testing
• 6.2. Global Genomic Urine Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Mail Order Pharmacies
• Speciality Pharmacies
• 6.3. Global Genomic Urine Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer Diagnosis
• Infectious Diseases
• Genetic Disorder Screening
• Health Monitoring
• 6.4. Global Genomic Urine Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Diagnostic Laboratories
• Research And Academic Institutions
• Other End Users
• 6.5. Global Genomic Urine Testing Market, Sub-Segmentation Of Deoxyribonucleic Acid Testing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Germline Mutation Analysis
• Somatic Mutation Detection
• Copy Number Variation (CNV) Testing
• Single Nucleotide Polymorphism Analysis
• 6.6. Global Genomic Urine Testing Market, Sub-Segmentation Of Ribonucleic Acid Testing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gene Expression Profiling
• Messenger Ribonucleic Acid Analysis
• Non-coding Ribonucleic Acid Detection
• Fusion Transcript Detection
• 6.7. Global Genomic Urine Testing Market, Sub-Segmentation Of Microbial Testing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Urinary Microbiome Profiling
• Pathogen Identification
• Antimicrobial Resistance Gene Detection
• Quantitative Microbial Load Analysis
• 6.8. Global Genomic Urine Testing Market, Sub-Segmentation Of Epigenetic Testing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Deoxyribonucleic Acid Methylation Analysis
• Histone Modification Profiling
• Chromatin Accessibility Testing

7. Genomic Urine Testing Market Regional And Country Analysis

• 7.1. Global Genomic Urine Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Genomic Urine Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Genomic Urine Testing Market

• 8.1. Asia-Pacific Genomic Urine Testing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Genomic Urine Testing Market, Segmentation By Testing Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Genomic Urine Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Genomic Urine Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Genomic Urine Testing Market

• 9.1. China Genomic Urine Testing Market Overview
• 9.2. China Genomic Urine Testing Market, Segmentation By Testing Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Genomic Urine Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Genomic Urine Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Genomic Urine Testing Market

• 10.1. India Genomic Urine Testing Market, Segmentation By Testing Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Genomic Urine Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Genomic Urine Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Genomic Urine Testing Market

• 11.1. Japan Genomic Urine Testing Market Overview
• 11.2. Japan Genomic Urine Testing Market, Segmentation By Testing Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Genomic Urine Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Genomic Urine Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Genomic Urine Testing Market

• 12.1. Australia Genomic Urine Testing Market, Segmentation By Testing Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Genomic Urine Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Genomic Urine Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Genomic Urine Testing Market

• 13.1. Indonesia Genomic Urine Testing Market, Segmentation By Testing Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Genomic Urine Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Genomic Urine Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Genomic Urine Testing Market

• 14.1. South Korea Genomic Urine Testing Market Overview
• 14.2. South Korea Genomic Urine Testing Market, Segmentation By Testing Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Genomic Urine Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Genomic Urine Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Genomic Urine Testing Market

• 15.1. Western Europe Genomic Urine Testing Market Overview
• 15.2. Western Europe Genomic Urine Testing Market, Segmentation By Testing Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Genomic Urine Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Genomic Urine Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Genomic Urine Testing Market

• 16.1. UK Genomic Urine Testing Market, Segmentation By Testing Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Genomic Urine Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Genomic Urine Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Genomic Urine Testing Market

• 17.1. Germany Genomic Urine Testing Market, Segmentation By Testing Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Genomic Urine Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Genomic Urine Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Genomic Urine Testing Market

• 18.1. France Genomic Urine Testing Market, Segmentation By Testing Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Genomic Urine Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Genomic Urine Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Genomic Urine Testing Market

• 19.1. Italy Genomic Urine Testing Market, Segmentation By Testing Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Genomic Urine Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Genomic Urine Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Genomic Urine Testing Market

• 20.1. Spain Genomic Urine Testing Market, Segmentation By Testing Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Genomic Urine Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Genomic Urine Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Genomic Urine Testing Market

• 21.1. Eastern Europe Genomic Urine Testing Market Overview
• 21.2. Eastern Europe Genomic Urine Testing Market, Segmentation By Testing Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Genomic Urine Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Genomic Urine Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Genomic Urine Testing Market

• 22.1. Russia Genomic Urine Testing Market, Segmentation By Testing Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Genomic Urine Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Genomic Urine Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Genomic Urine Testing Market

• 23.1. North America Genomic Urine Testing Market Overview
• 23.2. North America Genomic Urine Testing Market, Segmentation By Testing Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Genomic Urine Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Genomic Urine Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Genomic Urine Testing Market

• 24.1. USA Genomic Urine Testing Market Overview
• 24.2. USA Genomic Urine Testing Market, Segmentation By Testing Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Genomic Urine Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Genomic Urine Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Genomic Urine Testing Market

• 25.1. Canada Genomic Urine Testing Market Overview
• 25.2. Canada Genomic Urine Testing Market, Segmentation By Testing Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Genomic Urine Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Genomic Urine Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Genomic Urine Testing Market

• 26.1. South America Genomic Urine Testing Market Overview
• 26.2. South America Genomic Urine Testing Market, Segmentation By Testing Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Genomic Urine Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Genomic Urine Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Genomic Urine Testing Market

• 27.1. Brazil Genomic Urine Testing Market, Segmentation By Testing Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Genomic Urine Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Genomic Urine Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Genomic Urine Testing Market

• 28.1. Middle East Genomic Urine Testing Market Overview
• 28.2. Middle East Genomic Urine Testing Market, Segmentation By Testing Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Genomic Urine Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Genomic Urine Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Genomic Urine Testing Market

• 29.1. Africa Genomic Urine Testing Market Overview
• 29.2. Africa Genomic Urine Testing Market, Segmentation By Testing Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Genomic Urine Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Genomic Urine Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Genomic Urine Testing Market Competitive Landscape And Company Profiles

• 30.1. Genomic Urine Testing Market Competitive Landscape
• 30.2. Genomic Urine Testing Market Company Profiles
  • 30.2.1. Eurofins Scientific SE Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Laboratory Corporation of America Holdings Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Hologic Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Genomic Urine Testing Market Other Major And Innovative Companies

• 31.1. Illumina Inc.
• 31.2. Myriad Genetics Inc.
• 31.3. ARUP Laboratories
• 31.4. MedGenome Labs Ltd
• 31.5. GENETWORx LLC
• 31.6. MDxHealth SA
• 31.7. Nucleix Ltd.
• 31.8. Pacific Edge Ltd
• 31.9. Convergent Genomics Inc.
• 31.10. LynxDx Inc.
• 31.11. miR Scientific
• 31.12. RYND Biotech
• 31.13. UGenDx Ltd
• 31.14. Guardant Health
• 31.15. Exact Sciences

32. Global Genomic Urine Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Genomic Urine Testing Market

34. Recent Developments In The Genomic Urine Testing Market

35. Genomic Urine Testing Market High Potential Countries, Segments and Strategies

• 35.1 Genomic Urine Testing Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Genomic Urine Testing Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Genomic Urine Testing Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34860_Genomic_Urine_Testing_GMR_2025